Targeted therapies have been a mainstay of the renal cell carcinoma (RCC) treatment paradigm for the better part of two decades. Multikinase inhibitors of the vascular endothelial growth factor receptor tyrosine kinases (VEGF-TKIs) comprise nearly all targeted therapies in RCC, having been prospectively tested through large, multi-institutional phase III trials. ...
The LARCG (Latin American Renal Cancer Group) is a group of scientific and educational, multicentric, multidisciplinary and independent. It is not for profit, and the term of operation is indeterminate. It consists of Urologists, Pathologists and Oncologists, as well as professionals and researchers related to the field of health, belonging to Hospitals in Latin America, Spain and the United States.
Just in @KCA_Journal 👉🏻1/3rd patients with mRCC kidneycancer have bone mets. Scant data on development, prevention, prognosis and treatment of skeletal related events (SREs) in mRCC👉🏻Excellent systemic review by @PBarataMD @bilenma & team. @KidneyCancer https://t.co/Q6FoU859BQ
3Not typical for an #oncologist to sift through @NatRevNeph so leading my friends towards this DEFINITIVE article on #kidneycancer biomarkers written from start to finish by @NazliDizman, a resident now at @YaleMedicine. Please have a look! @neerajaiims @DrChoueiri @kamkalantar https://t.co/lj7XnQIAfF
https://t.co/D0UR98ZFiE
LARCG Work in progress!
